<DOC>
	<DOC>NCT00657254</DOC>
	<brief_summary>The study was designed to allow for the continuation of treatment with Sorafenib as a single agent to those patients who participated in a previous Sorafenib study that had reached its designated end-date and who were, in the opinion of the Investigator and the Sponsor, still benefiting from treatment.</brief_summary>
	<brief_title>Extension Program for Bay 43-9006</brief_title>
	<detailed_description />
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients who had participated in a previous sorafenib study that had completed, who did not meet withdrawal criteria of the previous study and who were, in the opinion of the investigator and sponsor still benefiting from treatment. Exclusion Criteria: The current cardiovascular situation of the patient was carefully reevaluated by both the investigator and the sponsor and an informed decision as to inclusion was then made. Substance abuse, medical, psychological or social conditions that may have interfered with the patient's participation in the study or evaluation of the study results. Known or suspected allergy to the investigational agent. Any condition that was unstable or which could jeopardise the safety of the patient and his/her compliance in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Extension</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Survival</keyword>
</DOC>